Wikisage, the free encyclopedia of the second generation, is digital heritage

Perampanel: Difference between revisions

From Wikisage
Jump to navigation Jump to search
m (wLink)
(4 intermediate revisions by the same user not shown)
Line 5: Line 5:


<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf</ref>
<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf</ref>
Perampanel was efficacious and well tolerated, despite the observation that the patient population exhibited characteristics of highly refractory [[epilepsy]]
<ref>http://n.neurology.org/content/suppl/2016/04/10/WNL.0000000000001930.DC3/french_950.pdf</ref>
==ATC==
==ATC==
https://www.whocc.no/atc_ddd_index/?code=N03AX22
https://www.whocc.no/atc_ddd_index/?code=N03AX22


[http://onlinelibrary.wiley.com/doi/10.1111/epi.12212/full Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies]
[http://onlinelibrary.wiley.com/doi/10.1111/epi.12212/full Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies]
{{wikidata|Q868658}}
<references/>
<references/>
[[Category:Anticonvulsant]]
[[Category:Anticonvulsant]]

Revision as of 19:24, 10 January 2018